Can overall survival be improved in elderly multiple myeloma patients?

Heeg, B. M., Liwing, J., Karstorp, S., Postma, M., Silvennoinen, R., Putkonen, M., Anttila, P., Remes, K., Abildgaard, N., Waage, A. & Nahi, H., 22-Jun-2015, In : Haematologica. 100, p. 517 1 p., Abstract: E1289.

Research output: Contribution to journalMeeting AbstractAcademic

  • B.M. Heeg
  • J. Liwing
  • S. Karstorp
  • M. Postma
  • R. Silvennoinen
  • M. Putkonen
  • P. Anttila
  • K. Remes
  • N. Abildgaard
  • A. Waage
  • H. Nahi
Background: The ongoing introduction of novel therapies for MM provides clinicians and patients various treatment options in numerous lines of treatment. Understanding the current treatment practices and the outcomes in different age groups is of vital importance to understand whether these new treatment should be used in patients from all age groups and where options for treatment optimization exist. Aims: (i) To describe treatment patterns and corresponding outcomes in terms of response, time to next therapy (TTNT) and overall survival (OS) of Nordic Multiple Myeloma (MM) patients with a focus on age. (ii) To investigate whether age affected the patients' probability of being treated with a conventional (e.g. melphelan prednisone) or a novel treatment (bortezomib, thalidomide or lenalidomide) and whether this treatment choice affected OS in the elderly. Methods: A retrospective analysis was performed on incident 2960 MMpatients from 24 hospitals in Denmark, Finland, Norway and Sweden. The database contained information on patient baseline characteristics such as age, gender, international staging system (ISS) stage, albumin, creatine, MM type and response, TTNT and OS over eight lines of treatment. The patients were stratified over three age groups (
Original languageEnglish
Article numberAbstract: E1289
Pages (from-to)517
Number of pages1
Publication statusPublished - 22-Jun-2015
Event20th Congress of the European Hematology Association Vienna, Austria, June 11–14, 2015 - Vienna, Austria
Duration: 11-Jun-201514-Jun-2015


20th Congress of the European Hematology Association Vienna, Austria, June 11–14, 2015


Vienna, Austria

Event: Conference


  • thalidomide, bortezomib, creatine, albumin, prednisone, lenalidomide, melphalan, human, aged, multiple myeloma, overall survival, patient, European, hematology, therapy, groups by age, proportional hazards model, staging, response time, Sweden, Finland, Denmark, hospital, Norway, data base, gender, propensity score, hazard ratio, stem cell transplantation, model, male

Download statistics

No data available

ID: 23333239